OKYO Pharma Limited Sponsored ADR (OKYO)
NASDAQ:OKYO
OKYO Stock Chart & Stats
$1.58
$0.09(7.75%)
At close: 4:00 PM EST
$1.58
$0.09(7.75%)
Day’s Range― - ―
52-Week Range$1.03 - $3.35
Previous CloseN/A
Volume700.83K
Average Volume (3M)131.52K
Market Cap
$81.16M
Enterprise Value$56.59M
Total Cash (Recent Filing)$4.22M
Total Debt (Recent Filing)$185.79K
Price to Earnings (P/E)―
Beta0.38
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding51,370,197
10 Day Avg. Volume47,624
30 Day Avg. Volume131,524
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-9.04
Price to Sales (P/S)0.00
P/FCF Ratio-27.67
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-26.03K
Enterprise Value/Ebitda-5.90
Forecast
1Y Price Target
$7.00Price Target Upside343.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Evidence Of EfficacyPhase 2 data showed meaningful pain reduction with urcosimod alongside directional improvements in corneal nerve structure versus placebo, indicating potential for both symptom relief and nerve restoration.
Experienced Leadership For CommercializationAppointment of a veteran ophthalmic executive as CEO with a record of launching category-defining therapies could accelerate development progress and future commercial readiness.
Regulatory Validation Of Endpoints And DesignFDA endorsed the proposed pain measurement and supported the study design and quality-of-life survey, offering regulatory alignment that strengthens the planned registrational trial pathway.
Bears Say
Limited Strength Of Imaging FindingsCorneal image improvements are based on a small exploratory analysis and need confirmation in larger trials before being viewed as definitive evidence of nerve restoration.
Multi‑front Development RisksProgram faces multiple risks across clinical, regulatory, commercial, financing, and intellectual property areas that could delay development or limit market prospects.
OKYO Pharma Limited Sponsored ADR News
OKYO FAQ
What was OKYO Pharma Limited Sponsored ADR’s price range in the past 12 months?
OKYO Pharma Limited Sponsored ADR lowest stock price was $1.03 and its highest was $3.35 in the past 12 months.
What is OKYO Pharma Limited Sponsored ADR’s market cap?
OKYO Pharma Limited Sponsored ADR’s market cap is $81.16M.
When is OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were OKYO Pharma Limited Sponsored ADR’s earnings last quarter?
Currently, no data Available
Is OKYO Pharma Limited Sponsored ADR overvalued?
According to Wall Street analysts OKYO Pharma Limited Sponsored ADR’s price is currently Undervalued.
Does OKYO Pharma Limited Sponsored ADR pay dividends?
OKYO Pharma Limited Sponsored ADR does not currently pay dividends.
What is OKYO Pharma Limited Sponsored ADR’s EPS estimate?
OKYO Pharma Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OKYO Pharma Limited Sponsored ADR have?
OKYO Pharma Limited Sponsored ADR has 51,370,197 shares outstanding.
What happened to OKYO Pharma Limited Sponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of OKYO Pharma Limited Sponsored ADR?
Currently, no hedge funds are holding shares in OKYO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OKYO Pharma Limited Sponsored ADR Stock Smart Score
Company Description
OKYO Pharma Limited Sponsored ADR
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO Stock 12 Month Forecast
Average Price Target
$7.00
▲(343.04% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
0.92% Other Institutional Investors
99.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---